Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NT5C2 | P49902 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17479346 | 0.92 | LGALS9 (0.38) | PDPK1BRD4ADORA3ADORA2AADORA1 | |
| SCHEMBL17465396 | 0.92 | LGALS9 (0.38) | PDPK1BRD4ADORA3ADORA2AADORA1 | |
| SCHEMBL17465435 | 0.91 | BRD4 (0.35) | PDPK1BRD4CSF1RNPSR1NT5C2 | |
| SCHEMBL17465397 | 0.83 | SMN1; SMN2 (0.35) | PDPK1BRD4CSF1RNPSR1NT5C2 | |
| SCHEMBL17465432 | 0.83 | BRD4 (0.35) | PDPK1BRD4CSF1RNPSR1NT5C2 | |
| SCHEMBL21837296 | 0.81 | TYMP (0.42) | BRD4RPS6KB1AURKARAB9ASCD | |
| SCHEMBL17465401 | 0.79 | BRD4 (0.35) | PDPK1BRD4CSF1RNPSR1NT5C2 | |
| SCHEMBL19644596 | 0.79 | BRD4 (0.35) | PDPK1BRD4CSF1RNPSR1NT5C2 | |
| SCHEMBL17465394 | 0.78 | PDPK1 (0.39) | PDPK1BRD4NPSR1NT5C2RPS6KB1 | |
| SCHEMBL21837294 | 0.78 | PRMT6 (0.33) | PDPK1BRD4CSF1RADORA1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023650-A1 | 4'-SUBSTITUTED-FURO[3,2-D]PYRIMIDINE AND -PYRROLO[3,2- D]PYRIMIDINE DERIVATIVES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3693367-B1 | THIENO [3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3693367-A1 | THIENO [3,2-D]PYRIMIDINES, FURO [3,2,D]PYRIMIDINES AND PYRROLO [3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3174870-B1 | THIENO [3,2-D]PYRIMIDINES, FURO [3,2,D]PYRIMIDINES AND PYRROLO [3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20180072755-A1 | THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9828388-B2 | Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-D]pyrimidines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828388-B2 | Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-D]pyrimidines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2016018697-A1 | THIENO [3,2-D] PYRIMIDINE, FURO [3,2,D] PYRIMIDINE, AND PYRROLO [3,2-D] PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2016-02-04 | — | — | WO | disclosed |
| US-20160024107-A1 | THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024107-A1 | THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024107-A1 | THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | DPYD, TYMS, TYMP | PDPK1 1029/4885BRD4 1908/4885CSF1R 2449/4885 |
| US-20180072755-A1 | THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | DPYD, TYMS, TYMP | PDPK1 1029/4885BRD4 1908/4885CSF1R 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.